Tango Therapeutics (NASDAQ:TNGX) Rating Lowered to Strong Sell at Zacks Research

Posted by Brenda Bartman on Oct 29th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other research firms have also recently weighed in on TNGX. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. initiated coverage on shares of Tango Therapeutics in a research note on Wednesday, July 15th. They set an “overweight” rating and a $46.00 price target for the company. HC Wainwright lifted their price objective on Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings upgraded Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Mizuho upped their price objective on Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.62.

Check Out Our Latest Report on Tango Therapeutics

Tango Therapeutics Price Performance

TNGX opened at $22.23 on Tuesday. The company has a market capitalization of $3.75 billion, a P/E ratio of -26.15 and a beta of 1.17. The firm’s fifty day moving average price is $23.67 and its two-hundred day moving average price is $22.11. Tango Therapeutics has a fifty-two week low of $7.37 and a fifty-two week high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). On average, equities research analysts expect that Tango Therapeutics will post -1.41 EPS for the current fiscal year.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the transaction, the insider owned 115,743 shares in the company, valued at approximately $2,832,231.21. The trade was a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jessica Newcomb sold 8,200 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider directly owned 59,121 shares in the company, valued at $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TNGX. Profund Advisors LLC raised its position in Tango Therapeutics by 48.8% in the 3rd quarter. Profund Advisors LLC now owns 62,319 shares of the company’s stock worth $1,555,000 after purchasing an additional 20,430 shares during the last quarter. Vise Technologies Inc. bought a new position in Tango Therapeutics in the 3rd quarter valued at $319,000. China Universal Asset Management Co. Ltd. boosted its position in Tango Therapeutics by 28.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 37,165 shares of the company’s stock valued at $908,000 after buying an additional 8,144 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Tango Therapeutics by 838.8% in the 3rd quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock valued at $116,000 after buying an additional 4,152 shares during the period. Finally, Guardian Partners Inc. acquired a new stake in shares of Tango Therapeutics in the 3rd quarter valued at $748,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.